Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Short term Debt (2020 - 2025)

Historic Short term Debt for Puma Biotechnology (PBYI) over the last 5 years, with Q3 2025 value amounting to $33.7 million.

  • Puma Biotechnology's Short term Debt fell 2561.94% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year decrease of 2561.94%. This contributed to the annual value of $45.3 million for FY2024, which is 3333.24% up from last year.
  • As of Q3 2025, Puma Biotechnology's Short term Debt stood at $33.7 million, which was down 2561.94% from $34.0 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Short term Debt registered a high of $45.3 million during Q1 2024, and its lowest value of $11.3 million during Q2 2023.
  • For the 4-year period, Puma Biotechnology's Short term Debt averaged around $34.7 million, with its median value being $34.0 million (2023).
  • Its Short term Debt has fluctuated over the past 5 years, first surged by 30000.88% in 2024, then tumbled by 2561.94% in 2025.
  • Quarter analysis of 4 years shows Puma Biotechnology's Short term Debt stood at $31.4 million in 2021, then grew by 8.17% to $34.0 million in 2023, then skyrocketed by 33.33% to $45.3 million in 2024, then fell by 25.62% to $33.7 million in 2025.
  • Its last three reported values are $33.7 million in Q3 2025, $34.0 million for Q2 2025, and $45.3 million during Q1 2025.